Skip to main content
Erschienen in: Current Atherosclerosis Reports 12/2013

01.12.2013 | Lipid and Metabolic Effects of Gastrointestinal Surgery (F Rubino, Section Editor)

Metabolic Surgery for Type 2 Diabetes: Appraisal of Clinical Evidence and Review of Randomized Controlled Clinical Trials Comparing Surgery with Medical Therapy

verfasst von: Harold E. Lebovitz

Erschienen in: Current Atherosclerosis Reports | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Bariatric surgical procedures were originally developed to treat morbid obesity where their benefits certainly outweigh their potential side effects. Although they are very beneficial in improving metabolic control in type 2 diabetes, there are many medical treatments that are also effective. The role of bariatric surgery as primary therapy for type 2 diabetes depends on whether the benefit exceeds the surgical and nutritional complications, which are significant. The ultimate role for bariatric surgery in treating type 2 diabetes can only be determined by large, long-term randomized clinical trials which compare clinical outcomes of bariatric surgery with those of current intensive medical treatment. The four reported small, mostly 1-year trials have shown superior glycemic control by surgery as compared with medical treatment, but at the expense of significant surgical complications and unknown nutritional liability. They show that future trials will have to be much larger and last for at least 5–10 years.
Literatur
1.
Zurück zum Zitat Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery. A systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery. A systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef
2.
Zurück zum Zitat Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393–411.PubMedCrossRef Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393–411.PubMedCrossRef
3.
Zurück zum Zitat Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013. doi:10.1210/jc.2013-2538.PubMed Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013. doi:10.​1210/​jc.​2013-2538.PubMed
4.
Zurück zum Zitat Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.PubMedCrossRef Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.PubMedCrossRef
5.
Zurück zum Zitat Schauer P, Berguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–85.PubMed Schauer P, Berguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–85.PubMed
6.
Zurück zum Zitat • Lee W-J, Hur KY, Lakadawala M, et al. Gastrointestinal metabolic surgery for treatment of diabetic patients: a multiinstitutional international study. J Gastrointest Surg. 2012;16:45–52. Two hundred patients with poorly controlled type 2 diabetes and BMI below 35 kg/m 2 underwent bariatric surgery. Of 87 patients followed up at 1 year, 72.4 % had remission of their diabetes. A better diabetes remission rate was achieved in patients with shorter duration of diabetes (less than 5 years), higher BMI (greater than 30 kg/m 2 ), and gastric bypass surgery as compared with restrictive procedures.PubMedCrossRef • Lee W-J, Hur KY, Lakadawala M, et al. Gastrointestinal metabolic surgery for treatment of diabetic patients: a multiinstitutional international study. J Gastrointest Surg. 2012;16:45–52. Two hundred patients with poorly controlled type 2 diabetes and BMI below 35 kg/m 2 underwent bariatric surgery. Of 87 patients followed up at 1 year, 72.4 % had remission of their diabetes. A better diabetes remission rate was achieved in patients with shorter duration of diabetes (less than 5 years), higher BMI (greater than 30 kg/m 2 ), and gastric bypass surgery as compared with restrictive procedures.PubMedCrossRef
7.
Zurück zum Zitat Lebovitz HE. Science, clinical outcomes and the popularization of diabetes surgery. Curr Opin Endocrinol Diabetes Obes. 2012;19:359–66.PubMedCrossRef Lebovitz HE. Science, clinical outcomes and the popularization of diabetes surgery. Curr Opin Endocrinol Diabetes Obes. 2012;19:359–66.PubMedCrossRef
8.
Zurück zum Zitat Lebovitz HE. Metabolic surgery for type 2 diabetes with BMI < 35 kg/m2. An endocrinologist’s perspective. Obes Surg. 2013;23:800–8.PubMedCrossRef Lebovitz HE. Metabolic surgery for type 2 diabetes with BMI < 35 kg/m2. An endocrinologist’s perspective. Obes Surg. 2013;23:800–8.PubMedCrossRef
9.
Zurück zum Zitat •• Brethauer SA, Aminian A, Romero-Talamas H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–37. This is an analysis of 217 patients with type 2 diabetes treated by bariatric surgery with a median follow-up of 6 years. The long-term complete remission rate was 24 %. Mean excess weight loss was 55 % and the mean reduction in HbA1c level fell from 7.5 to 6.5 %. The rate of recurrence of diabetes after initial remission was 19 %.PubMed •• Brethauer SA, Aminian A, Romero-Talamas H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–37. This is an analysis of 217 patients with type 2 diabetes treated by bariatric surgery with a median follow-up of 6 years. The long-term complete remission rate was 24 %. Mean excess weight loss was 55 % and the mean reduction in HbA1c level fell from 7.5 to 6.5 %. The rate of recurrence of diabetes after initial remission was 19 %.PubMed
10.
Zurück zum Zitat Iaconelli A, Panunzi S, De Gaetano A, et al. Effects of bilio-pancreatic diversion on diabetic complications. Diabetes Care. 2011;34:561–7.PubMedCrossRef Iaconelli A, Panunzi S, De Gaetano A, et al. Effects of bilio-pancreatic diversion on diabetic complications. Diabetes Care. 2011;34:561–7.PubMedCrossRef
11.
Zurück zum Zitat Heneghan HM, Cetin D, Navaneethan SD, et al. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis. 2013;9:7–14.PubMedCrossRef Heneghan HM, Cetin D, Navaneethan SD, et al. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis. 2013;9:7–14.PubMedCrossRef
12.
Zurück zum Zitat Dixon J, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.PubMedCrossRef Dixon J, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.PubMedCrossRef
13.
Zurück zum Zitat •• Schuaer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76. This was a randomized controlled trial comparing medical therapy with gastric bypass or sleeve gastrectomy in the treatment of 150 poorly controlled type 2 diabetic patients. Follow-up was 1 year. Remission of the diabetes (HbA1c level below 6 %) occurred in 12 % of the medically treated group, 42 % of the gastric bypass group, and 37 % of the sleeve gastrectomy group.CrossRef •• Schuaer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76. This was a randomized controlled trial comparing medical therapy with gastric bypass or sleeve gastrectomy in the treatment of 150 poorly controlled type 2 diabetic patients. Follow-up was 1 year. Remission of the diabetes (HbA1c level below 6 %) occurred in 12 % of the medically treated group, 42 % of the gastric bypass group, and 37 % of the sleeve gastrectomy group.CrossRef
14.
Zurück zum Zitat • Mingrone G, Panunzi S, De Gaetario A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85. This was a single-center randomized trial of 60 poorly controlled type 2 diabetic patients undergoing conventional medical therapy, gastric bypass surgery, or biliopancreatic diversion. At 2 years, remission of the diabetes (HbA1c level below 6.5 % and fasting blood glucose level below 100 mg/dl) occurred in 75 % of the gastric bypass patients, 95 % of the biliopancreatic diversion patients, and 0 % of the medically treated patients.PubMedCrossRef • Mingrone G, Panunzi S, De Gaetario A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85. This was a single-center randomized trial of 60 poorly controlled type 2 diabetic patients undergoing conventional medical therapy, gastric bypass surgery, or biliopancreatic diversion. At 2 years, remission of the diabetes (HbA1c level below 6.5 % and fasting blood glucose level below 100 mg/dl) occurred in 75 % of the gastric bypass patients, 95 % of the biliopancreatic diversion patients, and 0 % of the medically treated patients.PubMedCrossRef
15.
Zurück zum Zitat •• Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. The Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240–9. This was a 12-month randomized trial comparing gastric bypass surgery with intensive lifestyle–medical management in 120 type 2 diabetic patients. Forty-nine percent of the bariatric surgery group and 19 % of the medically treated group achieved the primary end point of HbA1c level below 7 %, LDL cholesterol level below 100 mg/dl, and systolic blood pressure below 130 mmHg. Four perioperative and six late postoperative complications occurred in the surgical group. Nutritional deficiencies occurred in 34 surgical patients and 12 medically treated patients.PubMedCrossRef •• Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. The Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240–9. This was a 12-month randomized trial comparing gastric bypass surgery with intensive lifestyle–medical management in 120 type 2 diabetic patients. Forty-nine percent of the bariatric surgery group and 19 % of the medically treated group achieved the primary end point of HbA1c level below 7 %, LDL cholesterol level below 100 mg/dl, and systolic blood pressure below 130 mmHg. Four perioperative and six late postoperative complications occurred in the surgical group. Nutritional deficiencies occurred in 34 surgical patients and 12 medically treated patients.PubMedCrossRef
16.
Zurück zum Zitat The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445–54.CrossRef The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445–54.CrossRef
17.
Zurück zum Zitat Smith MD, Patterson E, Wahed AS, et al. 30-day mortality after bariatric surgery: independently adjudicated causes of death in the longitudinal assessment of bariatric surgery. Obes Surg. 2011;21:1687–92.PubMedCrossRef Smith MD, Patterson E, Wahed AS, et al. 30-day mortality after bariatric surgery: independently adjudicated causes of death in the longitudinal assessment of bariatric surgery. Obes Surg. 2011;21:1687–92.PubMedCrossRef
18.
Zurück zum Zitat Inabnet III WB, Winegar DA, Sherif B, et al. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg. 2012;214:550–7.PubMedCrossRef Inabnet III WB, Winegar DA, Sherif B, et al. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg. 2012;214:550–7.PubMedCrossRef
19.
Zurück zum Zitat DeMaria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the bariatric outcomes longitudinal database. Ann Surg. 2010;252:559–67.PubMed DeMaria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the bariatric outcomes longitudinal database. Ann Surg. 2010;252:559–67.PubMed
20.
Zurück zum Zitat Romy S, Donadini A, Giusti V, et al. Roux-en-Y gastric bypass vs gastric banding for morbid obesity. A case-matched study of 442 patients. Arch Surg. 2012;147:460–6.PubMedCrossRef Romy S, Donadini A, Giusti V, et al. Roux-en-Y gastric bypass vs gastric banding for morbid obesity. A case-matched study of 442 patients. Arch Surg. 2012;147:460–6.PubMedCrossRef
21.
Zurück zum Zitat Heber D, Greenway FL, Kaplan LM, et al. Endocrine and nutritional management of the post-bariatric surgery patient: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:4823–43.PubMedCrossRef Heber D, Greenway FL, Kaplan LM, et al. Endocrine and nutritional management of the post-bariatric surgery patient: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:4823–43.PubMedCrossRef
22.
Zurück zum Zitat •• Bal BS, Finelli FC, Shope TR, et al. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol. 2012;8:544–56. This is an extensive review which summarizes the current knowledge of nutritional deficiencies that can occur in patients after bariatric surgery. It highlights the symptoms, frequencies, follow-up, and treatment options for the macronutrient and micronutrient disorders that occur following bariatric surgery.PubMedCrossRef •• Bal BS, Finelli FC, Shope TR, et al. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol. 2012;8:544–56. This is an extensive review which summarizes the current knowledge of nutritional deficiencies that can occur in patients after bariatric surgery. It highlights the symptoms, frequencies, follow-up, and treatment options for the macronutrient and micronutrient disorders that occur following bariatric surgery.PubMedCrossRef
23.
Zurück zum Zitat Clements RH, Katasani VG, Palepu R, et al. Incidence of vitamin deficiency after laparoscopic Roux-en-Y gastric bypass in a university hospital setting. Am Surg. 2006;72:1196–204. Clements RH, Katasani VG, Palepu R, et al. Incidence of vitamin deficiency after laparoscopic Roux-en-Y gastric bypass in a university hospital setting. Am Surg. 2006;72:1196–204.
24.
Zurück zum Zitat Aasheim ET. Wernicke encephalopathy after bariatric surgery. A systemic review. Ann Surg. 2008;248:714–20.PubMed Aasheim ET. Wernicke encephalopathy after bariatric surgery. A systemic review. Ann Surg. 2008;248:714–20.PubMed
25.
Zurück zum Zitat Ruz M, Carrasco F, Rojas P, et al. Iron absorption and iron status are reduced after Roux-en-Y gastric bypass. Am J Clin Nutr. 2009;90:527–32.PubMedCrossRef Ruz M, Carrasco F, Rojas P, et al. Iron absorption and iron status are reduced after Roux-en-Y gastric bypass. Am J Clin Nutr. 2009;90:527–32.PubMedCrossRef
26.
Zurück zum Zitat Johnson JM, Maher JW, Samuel I, et al. Effects of gastric bypass procedures on bone mineral density, calcium, parathyroid hormone and vitamin D. J Gastrointest Surg. 2005;9:1106–10.PubMedCrossRef Johnson JM, Maher JW, Samuel I, et al. Effects of gastric bypass procedures on bone mineral density, calcium, parathyroid hormone and vitamin D. J Gastrointest Surg. 2005;9:1106–10.PubMedCrossRef
27.
Zurück zum Zitat Salle A, Demarsy D, Poiner AL, et al. Zinc deficiency : a frequent and underestimated complication after bariatric surgery. Obes Surg. 2010;20:1660–70.PubMedCrossRef Salle A, Demarsy D, Poiner AL, et al. Zinc deficiency : a frequent and underestimated complication after bariatric surgery. Obes Surg. 2010;20:1660–70.PubMedCrossRef
28.
Zurück zum Zitat Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2013;9:159–91.PubMedCrossRef Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2013;9:159–91.PubMedCrossRef
29.
Zurück zum Zitat DCCT/EDIC investigators. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA. 2003;290:2159–67.CrossRef DCCT/EDIC investigators. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA. 2003;290:2159–67.CrossRef
30.
Zurück zum Zitat Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes. Diabetologia. 2009;52:2288–98.PubMedCrossRef Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes. Diabetologia. 2009;52:2288–98.PubMedCrossRef
31.
Zurück zum Zitat DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
32.
Zurück zum Zitat Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes. A systematic review. JAMA. 2013;309:2250–61.PubMedCrossRef Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes. A systematic review. JAMA. 2013;309:2250–61.PubMedCrossRef
33.
34.
Zurück zum Zitat Treating diabetes with bariatric surgery. BMJ. 2013;346:f3710. Treating diabetes with bariatric surgery. BMJ. 2013;346:f3710.
Metadaten
Titel
Metabolic Surgery for Type 2 Diabetes: Appraisal of Clinical Evidence and Review of Randomized Controlled Clinical Trials Comparing Surgery with Medical Therapy
verfasst von
Harold E. Lebovitz
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 12/2013
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-013-0376-y

Weitere Artikel der Ausgabe 12/2013

Current Atherosclerosis Reports 12/2013 Zur Ausgabe

Genetics (AJ Marian, Section Editor)

Pharmacology of Antiplatelet Agents

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Endothelial MicroRNAs and Atherosclerosis

Lipid and Metabolic Effects of Gastrointestinal Surgery (F Rubino, Section Editor)

From Bariatric to Metabolic Surgery: Definition of a New Discipline and Implications for Clinical Practice

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

So häufig greift rheumatoide Arthritis auf Organe über

21.05.2024 Rheumatoide Arthritis Nachrichten

Im Verlauf von rheumatoider Arthritis entwickeln viele Patienten extraartikuläre Manifestationen. Schwedische Forscher haben sich mit der Inzidenz und den Risikofaktoren befasst.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.